This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at Rubius' lead pipeline candidate, RTX-134 in phenylketonuria (PKU)

Ticker(s): RUBY, BMRN

Who's the expert?

A neurologist that specialises in metabolic disorders and has treated patients with PKU.

Interview Questions

Please tell us about your clinical experience. How many patients with PKU do you see on a yearly basis? How many of them have an aggravated level of the disease? How many of them do you diagnose as newborns?

Added By: c_admin

What is the standard of treatment for PKU patients? What is the optimal range of phenylalanine that you aim for in your patients and how do you achieve that?

Added By: c_admin

How big of an impact does diet make in the outcome of this disease? Do your patients take tyrosine or casein glycomacropeptide supplements, besides their drug treatments?

Added By: c_admin

What can you tell us about Rubius’ red blood cell engineering, do you believe a method like this could work in PKU, can it be brought to market?

Added By: c_admin

What are the fundamental differences between RTX-134 and Pegvaliase (Palynziq)? Is Rubius’ choice to deliver the enzyme phenylalanine ammonia lyase through red blood cells more efficient than Biomarin’s pegylated derivative via injection?

Added By: c_admin

Have you used Pegvaliase in your patients since its approval in May 2018? What feedback can you give us on its safety and efficacy, as compared to previous therapies?

Added By: c_admin

What can you tell us about Biomarin's Phase 2 PEG-PAL gene therapy? Does it have the potential to become important in the PKU space? What are the pros and cons of it so far?

Added By: c_admin

What advantages, if any do you think RTX-134 has over other therapies (sapropterin, pegvaliase, etc). If approved, how likely would you be to switch patients?

Added By: c_admin

Does the fact that Rubius’ RCTs lack a nucleus increase tolerability, compared to other cellular therapies? What is the risk of the cells continuing to divide, expand and differentiate uncontrollably, post-injection?

Added By: c_admin

Given that RBCs have a circulating time of approximately 120 days, what would a dosing schedule look like? Would the patient require frequent check-ups due to the unpredictable pharmacokinetics and biodistribution associated with cellular therapies?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.